<DOC>
	<DOCNO>NCT01541618</DOCNO>
	<brief_summary>The purpose study compare biomarker level Multiple Sclerosis ( MS ) patient begin Natalizumab .</brief_summary>
	<brief_title>A Study MSDx Complex 1 Marker Therapy Response Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Diagnosis clinically definite relapse remit MS ( RRMS ) 2 . Age 45 year old 3 . Willing able provide write informed consent 4 . Patient high disease activity . 5 . Patient begin Natalizumab ( Tysabri ) therapy . 1 . Any clinically significant disease MS likely interfere evaluation CDMS 2 . Known infectious hematological disease . 3 . Unwilling unable comply requirement protocol 4 . Subject gadolinium enhance MRI</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>RR Multiple Sclerosis</keyword>
</DOC>